Sierra, Josep M.Camoez, MarianaTubau, FeGasch, OriolPujol Rojo, MiquelMartín, RogelioDomínguez Luzón, Ma. Ángeles (María Ángeles)2016-04-132016-04-1320131932-6203https://hdl.handle.net/2445/97365Linezolid is an effective antimicrobial agent to treat methicillin-resistant Staphylococcus aureus (MRSA). Resistance to linezolid due to the cfr gene is described worldwide. The present study aimed to analyze the prevalence of the cfr-mediated linezolid resistance among MRSA clinical isolates in our area. A very low prevalence of cfr mediated linezolid resistance was found: only one bacteremic isolate out of 2 215 screened isolates. The only linezolid resistant isolate arose in a patient, previously colonized by MRSA, following linezolid therapy. Despite the low rate of resistance in our area, ongoing surveillance is advisable to avoid the spread of linezolid resistance.3 p.application/pdfengcc-by (c) Sierra, J.M. et al., 2013http://creativecommons.org/licenses/by/3.0/esStaphylococcus aureusUnitats de cures intensivesInfeccions respiratòriesStaphylococcus aureusIntensive care unitsRespiratory infectionsinfo:eu-repo/semantics/article6386522016-04-13info:eu-repo/semantics/openAccess23554998